CD3
Products for CD3
- Cat.No. Product Name Information
-
GC68858
Cevostamab
BFCR 4350A; RG 6160; RO 7187797
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based bispecific antibody that targets the near-membrane extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. Additionally, Cevostamab promotes effective synapse formation, enhancing T cell killing activity against MM tumor cells.
-
GC69127
Foralumab
NI-0401
Foralumab (NI-0401) is an orally effective humanized monoclonal antibody that targets CD3. Foralumab can modulate the immune response of human cells reconstructed from hematopoietic stem cells in NSG mice.
-
GC69512
Muromonab
Muromonab is a monoclonal antibody that targets the CD3 receptor. It can block all cytotoxic T cell functions. Muromonab is also used as an immunosuppressant to reduce acute solid organ transplant rejection reactions.
- GC72342 Otelixizumab Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
- GC72443 Pavurutamab Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA).
-
GC69985
Talquetamab
JNJ-64407564
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that can bind to both GPRC5D (a member of the G protein-coupled receptor family C5) and CD3, inducing T cell-mediated killing of MM cells expressing GPRC5 through recruitment and activation of T cells. Talquetamab (JNJ-64407564) has anti-tumor activity.
-
GC70011
Teplizumab
MGA-031; PRV-031
Teplizumab (MGA-031) is a monoclonal antibody that targets human CD3 and is of the Fc receptor type, non-binding subtype. Teplizumab can alleviate the loss of function in beta cells and is used for research on type 1 diabetes.